APLP1 and Alzheimer disease: Whether APLP1 peptides can be used as CSF AD biomarkers reflecting Aβ42 production needs to be investigated in large clinical studies, including early clinical stage of AD, AD dementia and control subjects, in which other CSF and imaging biomarkers are included.